Kaleido BioSciences, Inc. develops microbiome metabolic therapies. It offers treatment for hyperammonemia, a metabolic condition generally characterized by elevated levels of ammonia in the blood; infections caused by multi-drug resistant bacteria; chronic kidney disease; atherosclerotic cardiovascular disease; and drug or disease induced diarrhea. Kaleido BioSciences, Inc. has a collaboration agreement with Gustave Roussy Cancer Center to develop microbiome metabolic therapies in immuno-oncology; and a research collaboration with Washington University School of Medicine to explore the influence of microbiome metabolic therapies on microbial and host physiology and metabolism. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [01/13/2020 13:01 PST] Kaleido BioSciences, Inc. (OTC:KLDO), Down By 100.00% ($5.42) From $5.420 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [01/10/2020 07:44 PST] KLDO Expected to Trade Down Short Term
• [12/27/2019 11:45 PST] Kaleido BioSciences, Inc. (OTC:KLDO), Up By 100.00% ($5.62) From $5.620 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [12/26/2019 11:07 PST] Kaleido BioSciences, Inc. (OTC:KLDO), Up By 100.00% ($5.54) From $5.540 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [12/26/2019 07:37 PST] KLDO Expected to Trade Up After Bullish Patterns Develop
• [12/17/2019 07:41 PST] KLDO Expected to Trade Up After Bullish Patterns Develop